Liksivaptan

Liksivaptan
(IUPAC) ime
	N-[3-chloro-4-(5H-pyrrolo-[2,1-c][1,4]benzodiazepin- 10(11H)-ylcarbonyl)phenyl]-5-fluoro-2-methylbenzamide
Klinički podaci
Identifikatori
CAS broj	168079-32-1
ATC kod	nije dodeljen
PubChem	172997
ChEMBL	CHEMBL49429
Hemijski podaci
Formula	C27H21ClFN3O2
Mol. masa	473.926
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C27H21ClFN3O2/c1-17-8-9-19(29)13-23(17)26(33)30-20-10-11-22(24(28)14-20)27(34)32-16-21-6-4-12-31(21)15-18-5-2-3-7-25(18)32/h2-14H,15-16H2,1H3,(H,30,33) ; Key: PPHTXRNHTVLQED-UHFFFAOYSA-N
Farmakoinformacioni podaci
Trudnoća	?
Pravni status

Liksivaptan (VPA-985) je lek u fazi III kliničkih ispitivanja koji je razvila kompanija Cardiokine, Inc.. Liksivaptan se ispituje za primenu kod pacijenata sa hiponatremijom, što obuhvata pacijente sa srčanom insuficijencijom. Hiponatremija je elektrolitni poremećaj kod koga je koncentracija natrijuma u serumu niža od normalne. Liksivaptan može da pomogne pacijentima da eliminišu suvišne fluide uz zadržavanje elektrolita. U kliničkim ispitivanjima, Liksivaptan je demonstrirao tu sposobnost.^[4]

Hemija

Sintetički put liksivaptana.^[5]

Literatura

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
↑ „The balance study: Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient Evaluation”.
↑ Albrbright, J. D.; Reich, M. F.; Santos, E. G. D.; Dusza, J. P.; Sum, F.-W.; Venkatesan, A. M.; Coupet, J.; Chan, P. S.; Ru, X.; Mazandarani, H.; Bailey, T. (1998). „5-Fluoro-2-methyl-N-[4-(5H-pyrrolo[2,1-c- [1,4]benzodiazepin-10(11H)-ylcarbonyl)-3- chlorophenyl]benzamide (VPA-985): An Orally Active Arginine Vasopressin Antagonist with Selectivity for V2 Receptors”]. J. Med. Chem. 41: 2442.

Vanjske veze

	Portal Medicina
	Portal Hemija

Šablon:Diuretici Šablon:Neuropeptidni ligandi

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit

[4] „The balance study: Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient Evaluation”.

[5] Albrbright, J. D.; Reich, M. F.; Santos, E. G. D.; Dusza, J. P.; Sum, F.-W.; Venkatesan, A. M.; Coupet, J.; Chan, P. S.; Ru, X.; Mazandarani, H.; Bailey, T. (1998). „5-Fluoro-2-methyl-N-[4-(5H-pyrrolo[2,1-c- [1,4]benzodiazepin-10(11H)-ylcarbonyl)-3- chlorophenyl]benzamide (VPA-985): An Orally Active Arginine Vasopressin Antagonist with Selectivity for V2 Receptors”]. J. Med. Chem. 41: 2442.

[1]

[2]

[3]

[4]

[5]